63. Idiopathic thrombocytopenic purpura Clinical trials / Disease details


Clinical trials : 363 Drugs : 212 - (DrugBank : 43) / Drug target genes : 47 - Drug target pathways : 138

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-001429-33-PL
(EUCTR)
07/12/201509/10/2015Study to evaluate safety and efficacy in adult subjects with ITPOpen Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacyof BMS-986004 in Adult Subjects with Primary Immune Thrombocytopenia (ITP) Immune Thrombocytopenia
MedDRA version: 19.1;Level: LLT;Classification code 10036735;Term: Primary thrombocytopenia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Anti-CD40LdAb
Product Code: BMS-986004
INN or Proposed INN: N/A
Other descriptive name: anti-CD40L
Bristol-Myers Squibb International CorporationNULLNot RecruitingFemale: yes
Male: yes
80Phase 2United States;Canada;Poland;Australia;Russian Federation;Georgia;Moldova, Republic of
2EUCTR2014-001429-33-GB
(EUCTR)
24/11/201407/10/2014Study to evaluate safety and efficacy in adult subjects with ITP Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects with Primary Immune Thrombocytopenia (ITP) Immune Thrombocytopenia
MedDRA version: 19.0;Level: LLT;Classification code 10036735;Term: Primary thrombocytopenia;System Organ Class: 100000004851 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Anti-CD40LdAb
Product Code: BMS-986004
INN or Proposed INN: N/A
Other descriptive name: anti-CD40L
Bristol-Myers Squibb International CorporationNULLNot Recruiting Female: yes
Male: yes
80 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited States;Canada;Poland;United Kingdom